Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841
Brief Summary: The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).


Options:
A: Arm Label: PF-06700841 Oral Solution/Suspension; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 oral solution/suspension | Arm Label: PF-06700841 Tablet; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: PF-06700841 oral solution/suspension; Assigned to Arm(s): PF-06700841 Oral Solution/Suspension | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PF-06700841 tablet; Assigned to Arm(s): PF-06700841 Tablet
B: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
D: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ixekizumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ixekizumab, Placebo

Answer: A